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ABSTRACT
The 340B Drug Pricing Program, created by Congress in 1992 through the Veterans Health Care Act, has provided discounted
drug prices to hospitals and other health care organizations serving a wide population of low-income patients. Some 340B
programs use contract pharmacies, an arrangement whereby the hospital or health care organization signs a contract directly with
a pharmacy to provide covered pharmacy services at discounted prices.
The federal 340B Drug Pricing Program has provided access to reduced price prescription drugs to over 35,000 individual
healthcare facilities and sites certified by the U.S. Department of Health and Human Services (HHS), and clinics have served
more than 10 million people in all 50 states, plus commonwealths and U.S. territories. The 340B program has increased profits
for hospitals through contract pharmacies because they have still received the same reimbursement but acquired drugs at a lower
rate.
Keywords
340B Program, Covered entities, Pharmacy contracts
1 INTRODUCTION
The Federal 340B Drug Pricing Program was created by Congress in 1992 through the Veterans Health Care Act and has provided
discounted drug prices to hospitals and other health care organizations that serve a wide population of low-income patients
(HRSA, 2017a). The 340B program offers discounts to hospitals for the purchase of outpatient drugs regardless of the patient's’
ability to pay (Health Affairs, 2017). As many as one third of Americans living at or below 200% of the federal poverty level
have struggled to afford even modest prescription drug expenses (Bright et al., 2010). 340B pricing has not been applied to
generic drugs, but has been applied to over the counter drugs, if prescribed by a physician (Albrecht and Mudahar, 2015). The
sole purpose of the 340B program has been to use its savings incentives to help safety net providers increase their amount of
patient services (HHS, 2016). Initially, individuals with low income and/or uninsured were the main targeted patients (Conti and
Bach, 2014).
Under the 340B Program, a contract pharmacy has been defined as the arrangement in which the covered entity signs a contract
with a pharmacy to provide pharmacy services (Clark et al., 2014). Covered entities within the program have been considered as
facilities or programs that have been deemed eligible in the 340B statute to purchase drugs with the 340B discount and have
appeared within the Health Resources and Services Administration (HRSA) 340B Database (340B University, 2016).
Audits have been the mechanism that HRSA has used to ensure that more than 11,000 covered entities participating in the 340B
drug program were in compliance with government regulations (Vogel, 2015). HRSA has developed a 340B-specific protocol
involving a more in-depth review of 340B compliance: they have audited covered entities based upon risk and targeted
approaches under three various risk categories. The first category included high risk, which has depended on the volume of
purchases, increased complexity of program administration, and use of contract pharmacies. The second category has been lesser
risk, which has been audited by the HRSA and covered entities have been chosen at random from program types that have been
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considered a lesser risk. Finally, the targeted category, where audits have been predicted to trigger allegations of 340B noncompliance, which have not been limited to whistleblowers, manufacturers or covered entities themselves (Ingram, 2012). The
HRSA has managed the program and predicted in 2013 that approximately $3.8 billion would be saved on outpatient drugs and
has also estimated that hospitals would have a minimum discount of 22.5% with the use of the prospective payment system
(Kantarjian and Chapman, 2015).
That the 340B program is important and growing is indisputable. Between 2010 and 2015, the 340B program more than doubled
in size and between 2013 and 2015 alone it expanded by 66%. The program is forecasted to exceed $23 billion in total sales by
2021 and will exceed 2014 Medicare Part B drug reimbursement that same year, with growth largely be driven by expanded
utilization at existing 340B-covered entities through contract pharmacy programs and from practice acquisitions, physician
practice affiliations, and patient referrals (Vandervelde and Blalock, 2016).
Given the substantial and increasing size and mandate of the federal 340B Drug Pricing Program, we examine how it has affected
hospitals and contract pharmacies since its inception, and what might be required to better meet the needs of its intended target,
low-income Americans.
2 RESULTS
340B Covered Hospitals
Covered entities include six categories of hospitals: disproportionate share hospitals (DSHs), children’s hospitals and cancer
hospitals exempt from the Medicare prospective payment system, sole community hospitals, critical access hospitals, and rural
referral centers (Brennan et al., 2015). The requirements for eligibility of each hospital are presented in Table 1.
Table 1
Type of Hospital
Disproportionate
Shared Hospitals
(DSHs)

Children’s
Hospitals

Freestanding
Cancer Hospitals

Definition
Serve
a
significantly
disproportionate number of lowincome patients and receive
payments from the Centers for
Medicaid and Medicare Services to
cover the costs of providing care to
uninsured patients
Are inpatient
facilities
with
predominantly serving ages 18 or
younger

Independent, non-profit hospitals
that treat patients with cancer

Source: (HRSA, 2017)
To be eligible to participate in the 340B Drug Pricing
Program
Must meet the requirements of the 42 USC256b(a)(4)(L)

Must either have a disproportionate share adjustment percentage
greater than 11.75% for the most-recently filed cost report; or be
eligible under a separate indigent care calculation that meets
specific criteria including location in an urban area, 100+ beds
and net inpatient care revenues (excluding Medicare) for indigent
care of more than 30% of net during the cost reporting period in
with the discharges occur
For-profit hospitals are not eligible to participate
Must either have a disproportionate share adjustment percentage
greater than 11.75% for the most-recently filed cost report; or be
eligible under a separate indigent care calculation that meets
specific criteria including location in an urban area, 100+ beds
and net inpatient care revenues (excluding Medicare) for indigent
care of more than 30% of net during the cost reporting period in
which the discharges occur

Sole Community
Hospitals

Designated by the Centers for
Medicare and Medicaid Services

Rural Referral
Centers

Are high-volume acute care rural
hospitals that treat a large number of
complicated cases
Designated by the Centers for
Medicare and Medicaid Services

Critical Access
Hospitals

Exempt from the Medicare Prospective Payment System
Must have a disproportionate share adjustment percentage equal
to or greater than 8% for the most-recently filed Medicare cost
report and meet the requirements of 42 USC 256b(a)(4)(L)(i)
Have a disproportionate share adjustment equal to or greater than
8% for the most recently filed Medicare cost report and meet the
requirements of 42 USC 256b(a)(4)(L)(i)
Must meet the requirements of 42 USC 256b(a)(4)(L)(i)
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Hospitals in each of the categories are required to be (1) owned or operated by state or local government, (2) a public or private
non-profit corporation which has been formally granted governmental powers by state or local government, or (3) a private nonprofit organization that has a contract with a state or local government to provide care to low-income individuals who do not
qualify for Medicaid or Medicare (340 Health, 2017). To have qualified for 340B eligibility, a DSH must have a patient
population of 27.32% low-income patients, defined as Medicaid- eligible (but not eligible for Medicare Part A), or Medicare Part
A eligible patients who also qualify for federal Supplemental Security Income payments (Gricius and Wong, 2016). These authors
also suggested that rural referral centers and sole community hospitals have a threshold of 22.8%. Hospitals, which were 46%
percent of 340B-covered entity sites, account for nearly 90% of 340B purchases (Fein, 2016). In 2013, hospitals received 340B
discounts on an estimated 25% of their drug purchases, compared with only 3% of 2004 purchases (Fein, 2016).
The federal 340B Drug Pricing Program has provided access to reduced price prescription drugs to over 35,000 individual
healthcare facilities and sites certified by the U.S. Department of Health and Human Services (HHS) as "covered entities." In
turn, these organizations have served more than 10 million people in all 50 states, plus commonwealths and U.S. territories
(NCSL, 2017). These authors have also stated that covered entities spent $7 billion in 2013 on 340B drugs, which was 3 times
the amount that was spent 8 years prior (Brennan et al., 2015). The 340B Program was originally implemented into only lowincome communities, however, research suggested that facilities that registered after 2004 have been in higher-income
communities (Conti and Bach, 2014).
340B audit compliance
Since 2012, HRSA has conducted audits of covered entities to assess whether they complied with statutory prohibitions against
diversion and duplicate discounts. The latest audit results have revealed noncompliance rates that exceeded 69% and have
reflected challenges in covered entities’ ability to comply with statutory requirements and HRSA’s administration of the 340B
program (HRSA, 2017).
In order to remain compliant with the 340B program, covered entities must have registered all the pharmacy locations with which
the covered entity had a written contract in place to dispense drugs or provide services to patients of the covered entity under the
contract (Apexus, 2018).
HRSA must approve eligible entities, and covered entities must recertify their eligibility annually. Each site within a multilocation health system must qualify independently. A 340B hospital’s outpatient facility can participate in the 340B program
only if it is an “integral” part of the hospital, which HRSA defines as “a reimbursable facility included on the hospital’s Medicare
cost report” (Fein, 2016, p. 198). Several key focus areas exist for compliance, as assessed from the recent HRSA audit findings:
verification that the patient was eligible, that the prescribing provider was employed or under contract with the covered entity at
the time the prescription was written, and that the treating facility was registered in the HRSA database (Davison, 2017).
In addition, all off-site facilities and pharmacy locations should be registered accurately in the HRSA database. Internal controls
should be maintained for preventing duplicate discounts and diversion, such as a tracking system, standard reports, and a process
for mitigating problems when they were identified. Lastly, facilities should conduct regular internal monitoring and/or an
independent annual audit, or otherwise be able to demonstrate an adequate oversight mechanism (Pontell, 2014).
Contract pharmacies in hospitals
Many 340B covered hospitals have elected to dispense 340B drugs to patients through contract pharmacy services in order to
improve access and patient care: 72% of hospitals have elected to partake in this program to increase available resources and
have preceded to meet the needs of their low-income and rural patients (340 Health, 2017). The ability to dispense 340B drugs
to patients through contract pharmacy services has helped facilitate program participation for those covered entities that have not
had access to available or appropriate “in-house’’ pharmacy services (Wakefield, 2010), as well as those covered entities that
have access to ‘‘in-house’’ pharmacy services but have wish to supplement these services (HRSA, 2018). Additionally, contract
pharmacies have helped covered entities that wish to utilize multiple contract pharmacies to increase patient access to 340B drugs
by giving patients more pharmacy choices (NCPA, 2017). Pharmacies can be an expensive proposition: prescription expenditures
in clinics and nonfederal hospitals totaled $63.7 billion (an 11.9% increase from 2015) and $34.5 billion (a 3.3% increase from
2015), respectively (Schumock et al., 2017).
340B and hospitals
Research has proved that the 340B program has increased profits for hospitals through contract pharmacies because they have
still received the same reimbursement but acquired drugs at a lower rate. Patients’ out-of-pocket costs have increased, therefore
in some cases, it has only benefited the hospital and not their patients (Conti and Bach, 2013).
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It has been suggested that hospitals could retain the profits they have received on drugs purchased through contract pharmacies
under the 340B Program by dispensing these drugs at full price to fully insured patients (House Energy and Commerce
Committee, 2018; Kelly, 2014; Wright, 2014). Although drugs dispensed to hospital inpatients are supposed to be ineligible for
purchase through the 340B program, the tracking mechanism regarding how and for how much these drugs were purchased, and
to whom and at what price they were dispensed, is simply inadequate. Because 340B prescriptions purchased from contract
pharmacies cannot be identified at the time of payment, third-party payers are forced to reimburse 340B and non-340B outpatient
prescriptions at the same rate. Therefore, a 340B entity can “arbitrage” the system by buying drugs at the 340B rate and charging
for these same drugs at the non-340B rate. Medicare and commercial payers would not be able to identify the extent of the
“excess”, because providers are not required to report the payer for 340B prescriptions (Fein, 2016). For example, Conti and
Bach (2014) reported that Duke University Hospital profited $282 million in 5 years through outpatient departments and other
affiliated clinics from their participation in 340B. Duke University Hospital’s reply - “It is very difficult ... to accurately calculate
gross or net revenues from outpatient pharmaceuticals due to many factors, including the complicated reimbursement models for
pharmaceuticals” (Alexander, Neff and Garloch, 2015) – appears to support Fein’s (2016) concerns. While Duke University
Hospital’s response may well be accurate, it does not say anything positive about the ability of hospitals to track the costs of their
pharmaceuticals or how they may be participating in the 340B program. In any event, only 5% of the patients treated at Duke
University Hospital were uninsured, so the other 95% had some sort of insurance coverage; i.e., Medicare, Medicaid, or private
insurance (Stern, 2014).
It has also been noted that, because physicians in private practice are ineligible to purchase drugs for their private patients through
the 340B program, they have found it increasingly difficult to compete with hospital-based oncology practices, and consequently
many are selling their practices to hospitals which do to participate in the 340B Program. This practice would potentially provide
the physicians with anti-cancer drugs at a greatly reduced price due to the 340B drug discount, improving the profit margin of
the oncology practice and the hospital which owned that practice, while also greatly expanding the oncology patient population
served by the 340B hospital regardless of that patient population’s financial status. For example, Pollack (2013) noted that a
single practicing oncologist whose practice was acquired by a 340B hospital could gain an additional $1 million profit by
purchasing oncology drugs at a discount through the hospital’s participation in a 340B program. Since the average profit margin
in 2015 on 340B oncology drugs was 49% (Vandervelde and Blalock, 2016), it is not surprising that hospitals see a clear financial
incentive to aggressively obtain and market oncology services (Lagasse, 2018). Thus, the acquisition of oncology practices by
hospitals participating in the 340B Program has accelerated. In 2012 and 2013, 75% of community oncology practices were
purchased by hospitals with 340B programs (Community Oncology Alliance, 2014). Community Oncology Alliance (2016)
notes the continuance of this trend, with the rate of closing of community oncology practices having increased 87% per month,
which Hagen (2016) continues to attribute to the difficulties which community oncology practices have in try to competing with
the lower drug acquisition costs of hospitals participating in the 340B Program. These findings are disheartening from a financial
perspective, as Winfield and Muhlestein (2017), in a recent systematic literature review of 10 studies using either Medicare or
commercial claims datasets consisting of cancer diagnoses between 2011 and 2016, found that the average cost of cancer care
was 38% higher for patients treated in hospital-based practices compared with those treated at community clinics.
There is no requirement that hospitals spend any savings from the 340B program directly on patients, let alone on low-income
patients (Gellad and James, 2018; Hayes, 2017), or even a requirement that hospitals report to anyone, public or private, how the
savings are spent (Hayes, 2018; Teegardin, 2017). In fact, Desai and McWilliams (2018) in a recent study of general acute care
not-for-profit hospitals with 50 or more beds and a DSH percentage ± 10% of the 11.75% eligibility threshold, found “no evidence
of hospitals using the surplus monetary resources generated from administering discounted drugs to invest in safety-net providers,
provide more inpatient care to low-income patients, or enhance care for low-income groups in ways that would reduce mortality.”
Questions have been raised as to whether profits achieved as a result of the 340B Program are being used appropriately to serve
the needs of the nation’s most vulnerable (Freeman, 2017; Lee, 2014; Winegarden, 2017). Hospitals, on the other hand, claim
that the program is serving its intended purpose, as the drugs are being provided to vulnerable patients or the money is spent on
expanding low-income access to care and that analyses claiming otherwise are based upon faulty or inappropriate data (Testoni
and Hart, 2014). However, the Government Accountability Office (GAO, 2015) found that “12% of hospitals which participated
in the 340B program reported providing the lowest amounts of charity care across all hospitals in GAO’s analysis.” Similarly,
Conti and Bach (2014, p. 1786) found that “hospital-affiliated clinics that registered for the 340B program in 2004 or later served
communities that were wealthier and had higher rates of health insurance compared to communities served by hospitals and
clinics that registered for the program before 2004, leading them to the conclusion that “the 340B program is being converted
from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics.” More currently, the
Alliance for Integrity and Reform (2016), based upon FY 2012-2014 Medicare cost reports, reported that 64% of 340B hospitals
(all of which are not-for-profit) provide less charity care than the national average for all hospitals, including for-profit hospitals.
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3 DISCUSSION
We examined the growth and effects of the federal 340B Drug Pricing Program implementation and determined that it has
decreased hospital expenditures. Our literature review showed that 340B has decreased drug expenses for hospitals and increased
their profit margins, and the 340B Program continues to grow, especially recently.
Six different types of hospitals have been covered by 340B, with each one having to have met a certain threshold for qualification.
The 340B Program has been certified by the HHS and has allowed covered hospitals to have access to drugs at discounted prices.
As a result of this program, over 10 million patients in the US have received these benefits.
In order for the 340B Program to better demonstrate compliance with federal regulations, a stricter internal auditing process
should be established. The 340B statute explicitly authorizes HRSA to audit covered entities to be sure they are compliant with
the program. The internal auditing helps with compliance issues that may have been overlooked otherwise. The authorizing
officials at 340B-covered entities should be required to attest to being in full compliance with the 340B Program during
recertification, including compliance at all contract pharmacies. In addition, as part of recertification, covered entities should be
required to self-report to HRSA when they uncover a breach of 340B program requirements.
Contract pharmacies serve as a major component in the improvement of patient care and health care access. They have
significantly increased the number of low-income and rural patients able to receive prescription drugs who were unable to do so
before the implementation of 340B Program. However, many hospitals have also been found to provide drugs under the 340B
Program to fully insured patients in order to gain a larger profit, rather focusing on lower-income patients who are uninsured.
Future research areas
Continual participation in the 340B Program by hospitals, and persistent research will be necessary to confirm if hospitals have
neglected the program’s original goals and instead used the program becoming more profitable. The 340B Program has helped
to offset hospitals’ expenditures, but the ongoing increase in patients’ out-of-pocket costs would imply that hospitals have used
340B to benefit themselves rather than their low-income patients. Additional data would obviously be helpful in determining
where the additional funding associated with the 340B program payments to hospitals is being allocated by those hospitals. The
practical implications of 340B will need to be more closely monitored as more hospitals register sites in higher-income
communities.
4 CONCLUSIONS
The federal 340B Drug Pricing Program has continued to grow since being signed into law in 1992. Although it was originally
designed to serve the needs of low-income Americans, it appears to have morphed into a mechanism for healthcare providers to
enrich their bottom lines regardless of the income level of the population they serve, although the latter conclusion is disputable,
depending on one’s point of view. Additional, more comprehensive data obtained using a better cost accounting system for
providers and analysis by impartial parties will be necessary if the questions are to be resolved.
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